"Onkologie Unter Ems MVM mbH Studienzentrum Unter Ems"
Welcome,         Profile    Billing    Logout  
 4 Trials 
4 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Müller, Lothar
NCT04246684: Short-course Radiotherapy Versus Chemoradiotherapy, Followed by Consolidation Chemotherapy, and Selective Organ Preservation for MRI-defined Intermediate and High-risk Rectal Cancer Patients

Recruiting
3
702
Europe
Oxaliplatin, 85 mg/m2, Control arm, 5FU; 2400 mg/m2, 5-FU, control arm, 5FU, 250 mg/m2, Experimental arm: 5-FU, 5FU, 2400 mg/m2, experimental arm, Oxaliplatin 50 mg/m2, Experimental arm, Folinic Acid, 400 mg/m2, Radiotherapy control, 5x5 Gy: 25 Gy, Capecitabine, 1000 mg/m2, Oxaliplatin 85 mg/m2, radiotherapy experimental, 30 x 1,8 Gy: 54 Gy, Capecitabine, 825 mg/m2, Oxaliplatin, 130 mg/m2
Prof. Dr. med. Claus Rödel
Rectal Cancer Stage III
10/25
10/28
NCT01388621 / 2010-018849-59: Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer

Checkmark PROVE A PHASE II RANDOMIZED MULTICENTER STUDY OF PANITUMUMAB IN PLATINUM-SENSITIVE EPITHELIAL OVARIAN CANCER PATIENTS WITH KRAS WILD-TYPE
Checkmark PROVE A PHASE II RANDOMIZED MULTICENTER STUDY OF PANITUMUMAB IN PLATINUM-SENSITIVE EPITHELIAL OVARIAN CANCER PATIENTS WITH KRAS WILD-TYPE
Checkmark Panitumumab in platinum-sensitive epithelial ovarian cancer patients with KRAS wild-type: The PROVE-study, a phase II randomized multicenter study of the North-Eastern German Society of Gynaecologic Oncology.
 
2
140
Europe
Panitumumab, Vectibix, pegylated liposomal doxorubicin (PLD), Caelyx, Carboplatin, multiple generics in existence, Gemcitabine, Gemzar
WiSP Wissenschaftlicher Service Pharma GmbH, ClinAssess GmbH
Ovarian Cancer
07/14
07/15
INFINITY, NCT04389541: Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology

Recruiting
N/A
500
Europe
iOMEDICO AG, Bristol-Myers Squibb, Roche Pharma AG
Advanced Solid Tumors or Hematologic Malignancies
06/23
06/23
CARAT, NCT03374267: Registry Platform Renal Cell Carcinoma

Checkmark The sequential treatment of patients with metastatic renal cell carcinoma: Analyzes from the German registry platform CARAT
Checkmark [VIRTUAL] The SarsCov2 pandemic and patients with metastatic cancer in Germany - data from four prospective registry platforms
Checkmark [VIRTUAL] TKI versus CPI: Decision factors for the choice of first-line therapy in patients with advanced or metastatic renal cell carcinoma: analyzes from the German registry platform CARAT
Checkmark [VIRTUAL] TKI versus CPI: Decision factors for the choice of first-line therapy in patients with advanced or metastatic renal cell carcinoma: analyzes from the German registry platform CARAT
Checkmark [VIRTUAL] The SarsCov2 pandemic and patients with metastatic cancer in Germany - data from four prospective registry platforms
More
Recruiting
N/A
1000
Europe
Routine care as per site standard.
iOMEDICO AG
Renal Cell Carcinoma
12/24
12/24

Download Options